Search
Kiora Pharmaceuticals Inc
KPRXAdd to Watchlist
2.630USD
-0.030-1.13%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
10.50MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.13%
5 Days
+3.54%
1 Month
0.00%
6 Months
+30.20%
Year to Date
+33.50%
1 Year
-7.72%
Key Figures
2.680Open
2.740High
8.96KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.22%Turnover Ratio
2.660Prev. Close
2.620Low
18.59KTurnover
2.92P/E Static
0.75P/B
0.00%Div Yield TTM
-40.04%ROA
4.18052wk High
1.35Volume Ratio
3.59MNet Profit
3.99MShares
-2.6596EPS TTM
-0.39Beta
-58.78%ROE
1.76452wk Low
4.51%Amplitude
100.00%Gross Margin
10.50MMarket Cap
0.30Reward/Risk
3.82%Risk Rate
TradingKey Stock Score of Kiora Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Kiora Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 154 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.00.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Kiora Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Kiora Pharmaceuticals Inc Highlights
StrengthsRisks
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -0.99, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 843.30K shares, decreasing 41.12% quarter-over-quarter.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.85.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
12.000
Target Price
+351.13%
Upside Space
Kiora Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Kiora Pharmaceuticals Inc Info
Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is engaged in developing and commercializing therapies for the treatment of retinal diseases. The Company is engaged in developing KIO-301, a vision-restoring small molecule that acts as a photoswitch specifically created to restore vision in patients with inherited and age-related degenerative retinal diseases, including retinitis pigmentosa (RP). It is also developing KIO-104 for the treatment of retinal inflammatory diseases, including Diabetic Macular Edema (DME) and Posterior Non-Infectious Uveitis, a rare T cell-mediated, intraocular inflammatory disease. KIO-104 is a non-steroidal small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH) formulated for intravitreal delivery and is ideally suited to suppressing overactive T-cell activity to treat the underlying inflammation. KIO-101 focuses on treating the ocular manifestation of patients with autoimmune diseases.
Ticker SymbolKPRX
CompanyKiora Pharmaceuticals Inc
CEOStrem (Brian M)
Websitehttps://kiorapharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Kiora Pharmaceuticals Inc (KPRX)?
The current price of Kiora Pharmaceuticals Inc (KPRX) is 2.63.
What is the symbol of Kiora Pharmaceuticals Inc?
The ticker symbol of Kiora Pharmaceuticals Inc is KPRX.
What is the 52-week high of Kiora Pharmaceuticals Inc?
The 52-week high of Kiora Pharmaceuticals Inc is 4.18.
What is the 52-week low of Kiora Pharmaceuticals Inc?
The 52-week low of Kiora Pharmaceuticals Inc is 1.76.
What is the market capitalization of Kiora Pharmaceuticals Inc?
The market capitalization of Kiora Pharmaceuticals Inc is 10.50M.
Is Kiora Pharmaceuticals Inc (KPRX) currently rated as Buy, Hold, or Sell?
According to analysts, Kiora Pharmaceuticals Inc (KPRX) has an overall rating of Buy, with a price target of 12.00.
What is the Earnings Per Share (EPS TTM) of Kiora Pharmaceuticals Inc (KPRX)?
The Earnings Per Share (EPS TTM) of Kiora Pharmaceuticals Inc (KPRX) is -2.60.